First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2

BACKGROUND: Capsid virus-like particles (cVLP) have proven safe and immunogenic and can be a versatile platform to counter pandemics. We aimed to clinically test a modular cVLP COVID-19 vaccine in individuals who were naive to SARS-CoV-2. METHODS: In this phase 1, single-centre, dose-escalation, adj...

Descripción completa

Detalles Bibliográficos
Autores principales: Smit, Merel J, Sander, Adam F, Ariaans, Maud B P A, Fougeroux, Cyrielle, Heinzel, Constanze, Fendel, Rolf, Esen, Meral, Kremsner, Peter G, ter Heine, Rob, Wertheim, Heiman F, Idorn, Manja, Paludan, Søren Riis, Underwood, Alexander P, Binderup, Alekxander, Ramirez, Santseharay, Bukh, Jens, Soegaard, Max, Erdogan, Sayit M, Gustavsson, Tobias, Clemmensen, Stine, Theander, Thor G, Salanti, Ali, Hamborg, Mette, de Jongh, Willem A, McCall, Matthew B B, Nielsen, Morten A, Mordmüller, Benjamin G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9848408/
https://www.ncbi.nlm.nih.gov/pubmed/36681093
http://dx.doi.org/10.1016/S2666-5247(22)00337-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9848408/
https://www.ncbi.nlm.nih.gov/pubmed/36681093
http://dx.doi.org/10.1016/S2666-5247(22)00337-8

Ejemplares similares